* Tarsus Pharmaceuticals Inc TARS.OQ TARS.O is expected
to show a rise in quarterly revenue when it reports results on
August 8 for the period ending June 30 2024
* The Irvine California-based company is expected to report
revenue of $31.664 million, according to the mean estimate from
8 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Tarsus Pharmaceuticals
Inc is
for a loss of 92 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Tarsus
Pharmaceuticals Inc is $61.00, above its last closing price
of $23.14.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 -1.21 -1.20 -1.01 Beat 16.2
Dec. 31 2024 -1.36 -1.31 Beat 3.9
Jan. 1 0001 -1.37 -1.28 Beat 6.3
Jan. 1 0001 -1.06 -1.08 -1.17 Missed -8.5
Jan. -0.92 -0.94 -0.88 Beat 6.9
1 0001
Dec. 31 2022 -0.69 -0.49 Beat 29
Sep. 30 2022 -0.88 -0.97 -0.84 Beat 13.7
Jun. 30 2022 -0.61 -0.59 -0.24 Beat 59.4
This summary was machine generated August 7 at 01:12 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)